Antag Therapeutics secures €80M to advance weekly obesity treatment in clinical trials.

Antag Therapeutics, a biopharmaceutical firm, has secured €80 million in funding to advance its obesity treatment AT-7687, a weekly injection that targets the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR). The financing, led by Versant Ventures, will support clinical trials exploring AT-7687 as both a standalone treatment and in combination with GLP-1 therapies. The company aims to improve obesity and metabolic health outcomes.

4 months ago
6 Articles

Further Reading